Literature DB >> 29216639

Exendin-4 Induces Bone Marrow Stromal Cells Migration Through Bone Marrow-Derived Macrophages Polarization via PKA-STAT3 Signaling Pathway.

Ning Wang1, Jian Gao1, Min Jia1, Xue Ma1, Zhanxiang Lei2, Fei Da1, Fei Yan3, Huinan Zhang1, Ying Zhou1, Mingkai Li1, Gonghao He4, Jingru Meng1, Xiaoxing Luo1.   

Abstract

BACKGROUND/AIMS: The synthesis and degradation processes involved in bone remodeling are critically regulated by osteoblasts and osteoclasts. The GLP-1 receptor agonist Exendin-4 is beneficial for osteoblast differentiation and increases the number of osteoblasts.
METHODS: We constructed an ovariectomized model to evaluate the impact of Exendin-4 on bone formation in osteoporosis. A macrophage-depleted model was also created to investigate the effect of macrophages on bone formation. Thirty-two female WT C57BL/6 mice (aged 3 months) were randomly assigned to a normal control group and four ovariectomized (OVX) subgroups: OVX + vehicle group, OVX + Exendin-4 (4.2 µg/kg/day) group, OVX + chloride phosphate liposome group and OVX + chloride phosphate liposome + Exendin-4 group.
RESULTS: In this study, we found that Exendin-4 not only increased the number of osteoblasts and decreased the number of osteoclasts, but also increased the number of bone marrow stromal cells (BMSCs) at the bone surface. Moreover, we found that OVX mice treated with Exendin-4 increased TGF-β1 levels at the bone surface compared with that in OVX mice. Besides, Exendin-4 promoted the polarization of bone marrow-derived macrophages into M2 subtype and increased TGF-β1 secretion by the M2 subtype. Finally, we found that Exendin-4 induced macrophage polarization via the cAMP-PKA-STAT3 signaling pathway.
CONCLUSION: Exendin-4 promotes bone marrow-derived macrophage polarization to the M2 subtype and induces BMSC migration to the bone surface via PKA-STAT3 signaling.
© 2017 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Exendin-4; Macrophage; Migration; Polarization; TGF-β1

Mesh:

Substances:

Year:  2017        PMID: 29216639     DOI: 10.1159/000485776

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  6 in total

1.  Local administration of high-dose diabetes medicine exendin-4 inhibits orthodontic tooth movement in mice.

Authors:  Wei-Ren Shen; Hideki Kitaura; Jiawei Qi; Saika Ogawa; Fumitoshi Ohori; Takahiro Noguchi; Aseel Marahleh; Yasuhiko Nara; Pramusita Adya; Itaru Mizoguchi
Journal:  Angle Orthod       Date:  2021-01-01       Impact factor: 2.079

2.  METTL3 induces bone marrow mesenchymal stem cells osteogenic differentiation and migration through facilitating M1 macrophage differentiation.

Authors:  Hong Lei; Mingyu He; Xiaoqi He; Guanghui Li; Yang Wang; Yuelin Gao; Gege Yan; Quan Wang; Tao Li; Guoxin Liu; Weijie Du; Ye Yuan; Lei Yang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  Construction and performance of exendin-4-loaded chitosan-PLGA microspheres for enhancing implant osseointegration in type 2 diabetic rats.

Authors:  Shaojie Shi; Shuang Song; Xiangdong Liu; Guoqiang Zhao; Feng Ding; Wenshuang Zhao; Sijia Zhang; Yingliang Song; Wei Ma
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

4.  Exendin-4 and eldecalcitol synergistically promote osteogenic differentiation of bone marrow mesenchymal stem cells through M2 macrophages polarization via PI3K/AKT pathway.

Authors:  Yupu Lu; Shanshan Liu; Panpan Yang; Yuying Kou; Congshan Li; Hongrui Liu; Minqi Li
Journal:  Stem Cell Res Ther       Date:  2022-03-21       Impact factor: 6.832

Review 5.  GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential.

Authors:  Xiaoxuan Ma; Zhenghong Liu; Iqra Ilyas; Peter J Little; Danielle Kamato; Amirhossein Sahebka; Zhengfang Chen; Sihui Luo; Xueying Zheng; Jianping Weng; Suowen Xu
Journal:  Int J Biol Sci       Date:  2021-05-11       Impact factor: 6.580

6.  Exendin‑4 promotes osteogenic differentiation of adipose‑derived stem cells and facilitates bone repair.

Authors:  Banglian Deng; Wenzhong Zhu; Yansheng Duan; Yuqian Hu; Xuefeng Chen; Shuang Song; Zian Yi; Yingliang Song
Journal:  Mol Med Rep       Date:  2019-10-23       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.